PSP Research LLC Purchases Shares of 11,678 Xenon Pharmaceuticals Inc. $XENE

Posted by Brian Himes on May 20th, 2026

PSP Research LLC acquired a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 11,678 shares of the biopharmaceutical company’s stock, valued at approximately $523,000.

A number of other institutional investors have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its stake in Xenon Pharmaceuticals by 11.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,574 shares of the biopharmaceutical company’s stock worth $295,000 after buying an additional 675 shares during the period. Handelsbanken Fonder AB raised its stake in Xenon Pharmaceuticals by 31.3% during the 4th quarter. Handelsbanken Fonder AB now owns 29,800 shares of the biopharmaceutical company’s stock worth $1,336,000 after buying an additional 7,100 shares during the period. ProShare Advisors LLC raised its stake in Xenon Pharmaceuticals by 9.8% during the 4th quarter. ProShare Advisors LLC now owns 17,279 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 1,539 shares during the period. DNB Asset Management AS raised its stake in Xenon Pharmaceuticals by 9.5% during the 4th quarter. DNB Asset Management AS now owns 272,831 shares of the biopharmaceutical company’s stock worth $12,228,000 after buying an additional 23,750 shares during the period. Finally, Nan Fung Trinity HK Ltd. raised its stake in Xenon Pharmaceuticals by 43.1% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 226,965 shares of the biopharmaceutical company’s stock worth $10,173,000 after buying an additional 68,360 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Christopher John Kenney sold 2,771 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $166,564.81. Following the completion of the transaction, the insider directly owned 4,729 shares of the company’s stock, valued at $284,260.19. This represents a 36.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Andrea Difabio sold 2,607 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total value of $156,706.77. Following the completion of the transaction, the insider directly owned 4,893 shares of the company’s stock, valued at approximately $294,118.23. This represents a 34.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 296,707 shares of company stock valued at $17,845,365 over the last three months. Corporate insiders own 4.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on XENE shares. JPMorgan Chase & Co. boosted their price objective on Xenon Pharmaceuticals from $77.00 to $80.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. HC Wainwright boosted their price objective on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Needham & Company LLC decreased their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday, May 8th. Wolfe Research started coverage on Xenon Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $60.00 price objective for the company. Finally, Royal Bank Of Canada boosted their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $77.07.

Check Out Our Latest Stock Report on XENE

Xenon Pharmaceuticals Stock Up 0.6%

XENE stock opened at $54.05 on Wednesday. The firm has a market cap of $5.23 billion, a PE ratio of -11.50 and a beta of 0.65. The business has a 50 day moving average of $56.54 and a 200-day moving average of $47.35. Xenon Pharmaceuticals Inc. has a 12-month low of $28.19 and a 12-month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.17). During the same period in the prior year, the business earned ($0.83) earnings per share. On average, research analysts expect that Xenon Pharmaceuticals Inc. will post -4.88 earnings per share for the current year.

Xenon Pharmaceuticals Company Profile

(Free Report)

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.